75% OF ALL PATIENTS ENROLLED IN OUR PHASE 2B TRIAL
For the Company, patient recruitment has been an important priority for a long time and several measures have been put in place to increase recruitment. The measures include, among other things, expanded remittance networks, social media campaigns, individual incentive programs, dissemination of best practice, inspirational lectures by testers and Key Opinion Leaders and more. The efforts have resulted in a positive impact on recruitment and in 2022, a maximum level in the number of screened and recruited patients per week has been reached. Now Stayble can announce that 75% of the total population has been recruited.
Read more in the Press Release
Latest press releases
(SE) Kommuniké från årsstämma i Stayble Therapeutics
Idag, den 1 juni 2022, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.
Stayble Therapeutics publishes interim report for the first quarter
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes the interim report for the first quarter of 2022. The interim report is available as an attached document and on the Company’s website.
Financial reports
Get all the latest news
Or connect with us on linkedin
Bridging the therapeutic gap
About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.
Our market
Treating the root cause of the disease. Not just the symptoms.
Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.
Healthy disc
An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.
DEGENERATED UNTREATED DISC
When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.
Treated disc
By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.
LET’S MEET UP
We are participating in several conferences and industry events every year. Please do not hesitate to contact us to meet up.
Upcoming eventsNo events planned at the moment
Get in touch
We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you shortly.
info@stayble.se